This is a look at five stocks to consider buying before November. No, there isn’t a major election cycle, but these high ...

The stock market’s sentiment gauge is no different from any other pendulum, which occasionally causes swings in either overly ...

On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC’s ‘Closing Bell’ to discuss whether more volatility is ahead, following a volatile week in the market. Paul ...

Fueling Viking Therapeutics upside, analysts at Canaccord initiated coverage of the obesity treatment stock with a buy rating, and a price target of $106 a share With a short interest of 25%, Lemonade ...

CNX Resources is rated a Buy, with robust free cash flow and management’s proven financial acumen outweighing high short interest and leverage concerns. Short interest in CNX stands at 20.31%, far ...

Hedge funds aggressively ramped up record-breaking short positions on U.S. stocks last week, the highest since 2016 per Goldman Sachs data, amid AI disruption fears and four straight weeks of heavy ...

With 23% of its float short, Viking Therapeutics has been gaining momentum. In fact, since bottoming out at around $25, it’s now up to $38.88. With a short interest of 24.5%, Altimmune is another ...